Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Early Briefing and Review: Arena Pharma Inc., Spectrum Pharma Inc., Incyte Corp. Ltd., and Geron Corp.



  Early Briefing and Review: Arena Pharma Inc., Spectrum Pharma Inc., Incyte
                         Corp. Ltd., and Geron Corp.

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

LONDON, October 8, 2013

LONDON, October 8, 2013 /PRNewswire/ --

The U.S. equity market declined on Monday, October 7, 2013, with the S&P 500,
the Dow Jones Industrial Average, and the NASDAQ Composite falling by 0.85%,
0.90%, and 0.98%, respectively. Shares in the biotechnology industry ended on
a mixed note, even as the broader market posted losses. The major movers in
the industry included Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Spectrum
Pharmaceuticals Inc. (NASDAQ: SPPI), Incyte Corporation Ltd. (NASDAQ: INCY),
and Geron Corporation (NASDAQ: GERN). AAAResearchReports.com has released free
charting and technical research on these aforementioned companies. Register to
read these reports at:

http://www.aaaresearchreports.com/register/  

Shares in Arena Pharmaceuticals Inc. fell on Monday, before finishing the day
at $4.73, which is 2.27% lower than the previous close of $4.84. A total of
5.03 million shares were traded which is above the daily average volume of
4.98 million. The company's shares are currently trading at 57.00% lower than
the 52-week high of $11.00 and at 0.21% higher than the 52-week low of $4.72.
The company's shares have declined by 5.40% in the previous three trading
sessions, underperforming the S&P 500, which has fallen by 1.05% during the
same period. Moreover, Arena Pharmaceuticals Inc.'s stock is currently trading
below its 50-day and 200-day moving averages of $6.45 and $7.82, respectively.
Sign up for free report on ARNA at:

http://www.AAAResearchReports.com/ARNA100813.pdf

Spectrum Pharmaceuticals Inc. stock rose on Monday even as the broader market
fell. The company's shares fluctuated between $8.53 and $8.91 before finishing
the day at $8.66, up 2.00% from the previous day's price of $8.49. A total of
1.22 million shares were traded which is above the daily average volume of
0.91 million. Spectrum Pharmaceuticals Inc.'s stock has gained 4.72% in the
previous three trading sessions. In the last three months, the stock has
gained 9.90%, outperforming the S&P 500 which has advanced 2.71% during the
same period. Furthermore, Spectrum Pharmaceuticals Inc.'s shares are currently
trading above their 50-day moving average of $8.05. SPPI free technical report
can be accessed by signing up at:

http://www.AAAResearchReports.com/SPPI100813.pdf

Shares in Incyte Corp. fluctuated between gains and losses on Monday before
finishing the day at $38.27, which is 4.59% lower than the previous day's
close of $40.11. A total of 1.27 million shares were traded which is below the
daily average volume of 1.64 million. The company's shares are currently
trading at 8.77% lower than the 52-week high of $41.95 and at 148.02% higher
than the 52-week low of $15.43. The company's stock has surged 61.54% in the
previous three months, outperforming the S&P 500, which has advanced 2.71%
during the same period. Additionally, Incyte Corp.'s stock is currently
trading above its 50-day and 200-day moving averages of $32.68 and $24.05,
respectively. A free report on INCY can be accessed by registering at:

http://www.AAAResearchReports.com/INCY100813.pdf

Geron Corp.'s stock fluctuated between gains and losses on Monday before
closing the day flat. The company's shares traded between $3.15 and $3.44
before finishing the day at the previous day's close of $3.35. A total of 1.64
million shares were traded which is above the daily average volume of 1.26
million. Shares are currently trading at 15.19% lower than the 52-week high of
$3.95 and at 268.13% higher than the 52-week low of $0.91. Geron Corp.'s
shares have fallen by 1.47% in the previous three trading sessions. In the
last three months, the company's shares have rallied 118.95%, outperforming
the S&P 500, which has gained 2.71% during the same period. Further, Geron
Corp.'s shares are currently trading above their 50-day and 200-day moving
averages of $1.95 and $1.49, respectively. Register with AAA Research Reports
and download research on GERN for free at:

http://www.AAAResearchReports.com/GERN100813.pdf  

----

EDITOR NOTES:

 1. This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
 2. Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
 3. This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
 4. If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
 5. For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
 6. Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE AAA Research Reports

Contact: Peter F. Jones; +1(646)396-9126 (North America);
info@aaaresearchreports.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement